Serina Therapeutics Inc（SER）财务数据SERSerina Therapeutics Inc

Evaluating the bottom line, Serina Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -305.13%, provide a clear picture of how effectively SER converts its operational activities into shareholder value.

In the context of the broader market, SER competes directly with industry leaders such as WFCF and LFS. With a market capitalization of $71.12M, it holds a leading position in the sector. When comparing efficiency, SER's gross margin of N/A stands against WFCF's -16.73% and LFS's 32.23%. Such benchmarking helps identify whether Serina Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Serina Therapeutics has shown erratic financial performance with a net income of -$8.93 million in Q2 2026 and a forward P/E ratio of 0, indicating no earnings expected in the near term.